Claude Lardinois
Endocrinology, Diabetes & Metabolism · Reno, NVNPI 1689686677
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,780 of the $65,008 with a category attached, or 64.3%. 33 manufacturers reported payments, led by Lilly USA, LLC at 54.0% of the total. Reporting peaked in 2019 at $46,120 and has fallen 96.9% since, to $1,452 in 2025.
Across 220 payments — averaging $295.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$35K
- Sanofi-aventis U.S. LLC$13K
- Johnson & Johnson$9K
- Corcept Therapeutics$1K
- Xeris Pharmaceuticals, Inc.$1K
- Amgen$1K
- plus $5K from 27 others
What the payments were for
- Consulting fees$6,80010%
- Speaking & faculty fees$41,78064%
- Travel & lodging$5,3978%
- Food & beverage$10,92817%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 77 | $35,086 |
| Sanofi-aventis U.S. LLC | 23 | $12,646 |
| Johnson & Johnson | 19 | $8,961 |
| Corcept Therapeutics | 14 | $1,233 |
| Xeris Pharmaceuticals, Inc. | 4 | $1,077 |
| Amgen(2 entities) | 12 | $1,003 |
| AstraZeneca(2 entities) | 12 | $738 |
| Novo Nordisk | 12 | $610 |
| AbbVie | 4 | $413 |
| Amarin Pharma, Inc. | 5 | $369 |
| Boehringer Ingelheim | 7 | $338 |
| Bayer | 2 | $208 |
| Ascendis Pharma Endocrinology Inc | 3 | $205 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Radius Health, Inc. | 2 | $157 |
| Dexcom, Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 2 | $149 |
| Chiesi USA, Inc. | 1 | $148 |
| Gilead | 2 | $144 |
| Ascensia Diabetes Care US Inc. | 1 | $137 |
| Abbott | 2 | $129 |
| Soleno Therapeutics, Inc. | 1 | $119 |
| Merck | 3 | $115 |
| Recordati_rare_diseases_inc. | 1 | $113 |
| GRT US Holding, Inc. | 1 | $107 |
| Esperion Therapeutics, Inc. | 1 | $102 |
| Biomarin Pharmaceutical Inc. | 1 | $88 |
| GSK | 1 | $83 |
| Lexicon Pharmaceuticals, Inc. | 1 | $83 |
| Madrigal Pharmaceuticals | 1 | $37 |
| Novartis | 1 | $32 |
| Mannkind Corporation | 1 | $22 |
| Genentech, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,008 in reported general payments places this provider in the 85th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Other endocrinology, diabetes & metabolism in Reno
- Nitesh KuhadiyaReno$595K
- Lisa AbbottReno$130K
- Michael Raymund GonzalesReno$90K
- Sarah MoatsReno$23K
- Daniel CarusoReno$12K
- Robert FredericksReno$10K
- Polina ZykovaReno$7K
- David HowardReno$2K
- James AtchesonReno$2K
- Fadi HendeeReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.